Physicians and pharmacists’ clinical knowledge of statin therapy and monitoring parameters, and the barriers to guideline implementation in clinical practice

Abstract

Background Millions of individuals worldwide use statins, and their significant impact on cardiovascular disease (CVD) has been well-established. However, a lack of knowledge about the up-to-date guideline recommendations regarding statin therapy is a common barrier to implementation in clinical practice. Therefore, the present study aimed to assess the current clinical knowledge about statin therapy and its monitoring parameters. Also, we evaluated the barriers to cholesterol management guideline implementation in Yemen. Methods This observational cross-sectional study was conducted over four months, from June/2021 to September/2021, in Sana’a, Yemen. A validated questionnaire was distributed face-to-face to 650 participants (350 physicians and 300 pharmacists). Physicians and pharmacists from governmental and private hospitals and those working in private clinics or community pharmacies were included in the study. Results A total of 496 participants filled out the survey, with 22 being excluded due to incomplete data. So, the study has an overall response rate of 72.9% (474). The majority of pharmacists (81.8%) and physicians (78.7%) could not identify the patient group that needed ASCVD risk assessment before statin therapy initiation. Although a significant proportion of respondents knew of the fact that high-intensity statins are recommended for patients with ASCVD (65.4%) and primary hypercholesterolemia (58.4%), the majority of physicians and pharmacists could not identify the high (61.6% and 66.7.3%, respectively) and moderate statin-intensity doses (72.2% and 68.6%, respectively). Only 21.9% of all respondents knew that atorvastatin and rosuvastatin can be administered at any time of the day. Similarly, a low overall rate of respondents (19.6%) knew that atorvastatin does not need dose adjustment in chronic kidney diseases, with a statistically significant difference in knowledge between physicians and pharmacists (12.5% vs. 25.6%, p <0.001, respectively). Notably, only 39.2% of participants were aware that statins are not safe to use during breastfeeding. Around half of respondents (52.3%) correctly identify the duration (4 to 12 weeks) at which LD-C measuring is recommended after therapy initiation or dose change. The lowest knowledge scores for respondents were related to statin-drug interactions. Age, experience, degree, and previous guideline exposure were all significantly associated with the knowledge scores (p <0.05). The four most perceived barriers to implementing cholesterol management guidelines were no audit on adherence to the guidelines in the workplace (73.4%), insufficient resources to adequately implement and follow up on the guideline’s recommendations (73.6%), patient’s financial status (75.7%), and lack of familiarity about the guideline’s latest recommendations (63.3%). Conclusion Physicians and pharmacists had suboptimal clinical knowledge regarding statin therapy, dose intensities, drug-drug interaction, contraindications, and monitoring parameters. Therefore, physicians’ and pharmacists’ educational interventions regarding the up-to-date recommendation about statins are recommended.

  Lovastatin Use in Transplant: A Review and Survey

“…More specifically, several respondents showed a lack of knowledge on the ideal timing for taking statins, the suggested dose intensities for various patient cohorts, and the situations when taking statins should not be done, such as when a woman is pregnant or nursing. These findings highlight a pressing need for targeted educational interventions and comprehensive training programs aimed at enhancing healthcare workers' knowledge [4]. The goal of this study is to evaluate the literature on the perspectives on lovastatin use in cardiac transplant settings.…”

Closing the Gaps in Care of Dyslipidemia: Revolutionizing Management with Digital Health and Innovative Care Models

“…Furthermore, the United States Preventive Services Task Force’s conclusion that there is insufficient evidence to recommend initiation of statin therapy for ASCVD primary prevention among adults aged 76 years and older [ 77 ], mostly owing to a lack of dedicated RCTs including this demographic, may be related to underuse of effective interventions among healthy older adults [ 78 ]. Lastly, lack of clinician knowledge of important statin drug interactions may possibly lead to adverse effects, which might play a role in statin discontinuation [ 79 ].…”